Financial Data and Key Metrics Changes - Group revenue for Q3 FY2025 was $1.29 billion, representing an 8% increase year-over-year and a 9% increase in constant currency terms [44] - Gross margin increased by 140 basis points to 59.9%, driven by manufacturing and logistics efficiencies, as well as favorable shifts in product mix [48][49] - Net income for the March quarter increased by 11%, with non-GAAP diluted earnings per share also increasing by 11% to $2.37 [54] Business Line Data and Key Metrics Changes - Device sales globally increased by 7%, while masks and other sales increased by 12% on a constant currency basis [46] - In the US, Canada, and Latin America, device sales increased by 6%, and masks and other sales increased by 13% [47] - Residential care software revenue increased by 10% on a constant currency basis, supported by strong performance from the Medifox DAN software vertical [47] Market Data and Key Metrics Changes - Sales in Europe, Asia, and other regions increased by 8% on a constant currency basis [45] - The company is closely monitoring the evolving global trade environment, particularly in the area of tariffs, but does not expect significant impacts due to existing tariff exemptions [11][55] Company Strategy and Development Direction - The company is focused on expanding its digital health ecosystem and enhancing its brand awareness to capture a larger share of the sleep health market [27][29] - A new manufacturing facility in Calabasas, California, is set to open in June 2025, which will double the manufacturing footprint in the US and increase production capacity [57] - The company aims to improve the lives of 500 million people by 2030, emphasizing its commitment to innovation and patient care [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to thrive amid global uncertainties, citing a strong balance sheet and operational efficiency [13][60] - The company is actively tracking metrics related to patient flow and treatment adherence, aiming to reduce wait times for diagnostics and therapy [81][82] - Management highlighted the importance of ongoing investments in R&D, which are expected to drive long-term growth [18][52] Other Important Information - The company plans to increase its share buyback program to approximately $100 million per quarter starting in Q4 FY2025 [60] - Cash flow from operations for the quarter was $579 million, including a tax refund of $107 million [58] Q&A Session Summary Question: Can you talk us through the factors that attributed to the gross margin expansion? - Management indicated that manufacturing and distribution efficiencies were the primary drivers, along with favorable product mix and component costs [67][68] Question: How are you tracking the investments related to sleep apnea diagnostics? - Management is tracking metrics such as time to titration and therapy onset, emphasizing the importance of reducing backlogs in sleep labs [81][82] Question: Can you provide an update on the GLP-1 medications and their impact on new patient funnels for CPAP? - Management noted that while GLP-1s are being rolled out, they are proactively educating primary care physicians to drive referrals for sleep apnea therapy [103][106] Question: What is the expected impact of US tariffs on your financial results? - Management confirmed that existing tariff exemptions apply to their products, and they do not expect significant financial impacts from new tariffs [55][132] Question: Can you elaborate on the increase in share buybacks and capital allocation? - Management expressed confidence in increasing share buybacks due to strong operating cash flows and a robust business model, while also considering M&A opportunities [92][96]

Core Insights - ResMed reported $1.29 billion in revenue for the quarter ended March 2025, a year-over-year increase of 7.9% and an EPS of $2.37 compared to $2.13 a year ago, exceeding the Zacks Consensus Estimate of $1.28 billion by 0.53% [1] Financial Performance - The company delivered an EPS surprise of 0.42%, with the consensus EPS estimate being $2.36 [1] - Shares of ResMed have returned -3.3% over the past month, while the Zacks S&P 500 composite changed by -6.6% [3] Regional Performance - U.S., Canada, and Latin America - Devices: $422.70 million, a change of +5.9% year over year, compared to the average estimate of $426.47 million [4] - U.S., Canada, and Latin America - Masks and other: $326.70 million, representing a +13.4% change year over year, exceeding the estimate of $318.76 million [4] - Combined Europe, Asia, and other markets - Total: $381.30 million, a +5.5% change year over year, compared to the estimate of $377.86 million [4] - Combined Europe, Asia, and other markets - Devices: $253.50 million, a +6.1% change year over year, exceeding the estimate of $249.75 million [4] - Combined Europe, Asia, and other markets - Masks and other: $127.70 million, a +4.2% change year over year, slightly below the estimate of $128.11 million [4] - U.S., Canada, and Latin America - Total: $749.30 million, a +9% change year over year, compared to the estimate of $745.22 million [4] Global Revenue Breakdown - Global revenue - Total Sleep and Breathing Health: $1.13 billion, a +7.8% change year over year, exceeding the estimate of $1.12 billion [4] - Global revenue - Residential Care Software: $161.20 million, a +8.9% change year over year, slightly above the estimate of $161.15 million [4] - Global revenue - Total Devices: $676.20 million, a +6% change year over year, in line with the estimate of $676.22 million [4] - Global revenue - Total Masks and other: $454.40 million, a +10.6% change year over year, exceeding the estimate of $446.86 million [4]

Financial Performance - Net revenue for Sleep and Breathing Health products reached $1,130,575, an increase of 7.8% compared to $1,049,023 in the same quarter last year[12]. - Total net revenue for the quarter was $1,291,736, up 7.9% from $1,196,980 in the prior year[12]. - Gross profit for the quarter was $766,409, representing a gross margin of approximately 59.3%[12]. - Net income for the quarter was $365,041, a 21.5% increase from $300,492 in the same quarter last year[12]. - Basic earnings per share increased to $2.49, up from $2.04 in the prior year[12]. - Total revenue for the nine months ended March 31, 2025, reached $3,798,334, up 9.7% from $3,462,102 in the prior year[29]. - Net income for the nine months ended March 31, 2025, was $1,021,018, an increase of 40% compared to $728,715 for the same period in 2024[21]. - Diluted earnings per share for the nine months ended March 31, 2025, was $6.93, compared to $4.94 for the same period in 2024[84]. - For the three months ended March 31, 2025, net revenue increased to $1,291.7 million, up $94.8 million or 8% from $1,197.0 million for the same period in 2024[130]. - Net income for the three months ended March 31, 2025, was $365.0 million, an increase of $64.5 million or 21% from $300.5 million for the same period in 2024[167]. Assets and Liabilities - Total current assets increased to $3,208,420, compared to $2,357,719 as of June 30, 2024[8]. - Total assets reached $7,566,822, up from $6,872,394 in the previous year[8]. - Total liabilities were $2,020,689, slightly up from $2,008,351 as of June 30, 2024[8]. - Stockholders' equity increased to $5,546,133, compared to $4,864,043 in the previous year[8]. - Cash and cash equivalents at the end of the period were $932,711, significantly up from $237,910 at the end of the previous year[21]. - Total inventories as of March 31, 2025, amounted to $862,641 thousand, up from $822,250 thousand on June 30, 2024, representing an increase of 4.9%[53]. - Total prepaid expenses and other current assets increased to $505,243 thousand as of March 31, 2025, compared to $459,833 thousand as of June 30, 2024, reflecting an increase of approximately 9.1%[55]. - Net property, plant, and equipment decreased to $535,339 thousand as of March 31, 2025, from $548,025 thousand as of June 30, 2024, a decline of about 2.7%[55]. - Total debt decreased to $673,032 thousand as of March 31, 2025, from $707,213 thousand as of June 30, 2024, a reduction of approximately 4.8%[69]. Dividends and Shareholder Returns - The company declared a dividend of $0.53 per share, up from $0.48 in the same quarter last year[12]. - The company declared dividends of $0.48 per common share, totaling $233,290 for the nine months ended March 31, 2025[21]. - Cash dividends paid during the three months ended March 31, 2025, totaled $77.7 million, with a declared cash dividend of $0.53 per common share[189]. Research and Development - Research and development investment for the three months ended March 31, 2025, was $83.9 million, representing 6.5% of net revenues[124]. - Research and development expenses for the three months ended March 31, 2025, increased to $83.9 million, up $6.9 million or 9% from $77.1 million for the same period in 2024[153]. - For the nine months ended March 31, 2025, research and development expenses rose to $244.8 million, an increase of $18.2 million or 8% compared to $226.7 million for the same period in 2024[155]. Cash Flow and Investments - The company reported a net cash provided by operating activities of $1,212,822 for the nine months ended March 31, 2025, compared to $961,146 in 2024, representing a 26% increase[21]. - Cash provided by operating activities increased to $1,212.8 million for the nine months ended March 31, 2025, up from $961.1 million for the same period in 2024, representing a 26.2% increase[185]. - Cash used in investing activities decreased to $66.3 million for the nine months ended March 31, 2025, compared to $223.3 million for the same period in 2024, a reduction of 70.3%[187]. - Cash used in financing activities was $442.4 million for the nine months ended March 31, 2025, down from $726.0 million in the prior year, a decrease of 39.2%[188]. Segment Performance - Revenue from the Sleep and Breathing Health segment for the nine months ended March 31, 2025, was $3,323,905, compared to $3,029,915 in 2024, reflecting a growth of 9.7%[29]. - Total net revenue for the Sleep and Breathing Health segment was $1,130,575 thousand for the three months ended March 31, 2025, compared to $1,049,023 thousand for the same period in 2024, reflecting an increase of 7.8%[51]. - Total net revenue for the Residential Care Software segment was $161,161 thousand for the three months ended March 31, 2025, compared to $147,957 thousand for the same period in 2024, indicating an increase of 8.5%[51]. - Total net operating profit for the Sleep and Breathing Health segment was $494,796 thousand for the three months ended March 31, 2025, compared to $456,182 thousand for the same period in 2024, an increase of 8.5%[51]. - Net revenue from Residential Care Software for the three months ended March 31, 2025, increased to $161.2 million, an increase of $13.2 million or 9% compared to $148.0 million for the same period in 2024[136]. Debt and Financing - The company has a senior unsecured revolving credit facility of $1,500 million, with $1,500 million available for drawdown as of March 31, 2025[75]. - The interest rate on outstanding principal amounts under the credit agreements was 5.1% as of March 31, 2025[73]. - The company maintained a consolidated funded debt to consolidated EBITDA ratio of no more than 3.50 to 1.00, in compliance with debt covenants[78]. - The company was in compliance with its debt covenants as of March 31, 2025, with $675.0 million outstanding under various credit agreements[80]. Other Key Metrics - The effective income tax rate for the three months ended March 31, 2025, was 12.6%, down from 20.0% for the same period in 2024[163]. - The company recorded no restructuring expenses during the three and nine months ended March 31, 2025, compared to $64.2 million in restructuring charges for the same period in 2024[159]. - The company recorded net unrealized losses of $8.2 million for equity investments in non-marketable and marketable securities for the nine months ended March 31, 2025[65]. - The company executed foreign cross-currency swaps as net investment hedges to mitigate foreign currency risk associated with changes in spot rates between USD and EUR[99].